PHILADELPHIA (February 21, 2025) — Fox Chase Cancer Center’s Hossein Borghaei, DO, MS, Elizabeth Plimack, MD, MS, and Lorenzo Galluzzi, PhD, have been named to the 2024 list of Highly Cited Researchers by Clarivate, a leading global provider of transformative intelligence.
“We are proud to have in our midst researchers and physicians whose work plays an essential role in the development and improvement of cancer treatment worldwide,” said Jonathan Chernoff, MD, PhD, Cancer Center Director. “With three of our scientists named to this list, Fox Chase is well represented as a place where cutting-edge, meaningful cancer research is being done every day.”
Galluzzi, an Associate Professor in the Cancer Signaling and Microenvironment Research Program, was nominated in two listed fields, Immunology and Molecular Biology & Genetics, a distinction held by only 6% of the honorees.
Borghaei is Chief of the Division of Thoracic Medical Oncology and a Professor in the Department of Hematology/Oncology, and Plimack is Deputy Director at Fox Chase and a Professor in the Department of Hematology/Oncology.
Since its launch in 2001, the Highly Cited Researchers list has identified clinicians and scientists from around the globe who have demonstrated exceptional influence. The organization uses data from the Web of Science Core Collection citation index, as well as qualitative analysis performed by bibliometric experts and data scientists at the Institute for Scientific Information at Clarivate.
The annual listing highlights those individuals at universities, research institutes, and commercial organizations who have authored “multiple Highly Cited Papers which rank in the top 1% by citations for their field(s) and publication year in the Web of Science over the past decade,” according to Clarivate. However, citation activity is not the sole selection indicator.
Highly cited papers with more than 30 authors are excluded from the analysis, which makes being included on the list even more impressive because guideline panels, consensus statements, and large national clinical trials with many contributors, sometimes hundreds, tend to generate a large number of citations that do not necessarily reflect the contributions of each author.
Borghaei, who specializes in lung cancer research, is also a member of the Cancer Signaling and Microenvironment Research Program. His lab concentrates on the development of new cancer treatments, with an emphasis on the use of immunotherapy and monoclonal antibodies. He is also active in clinical trials.
Plimack specializes in the treatment of kidney, bladder, and prostate cancer. Her research efforts focus on the development of new therapies for bladder and kidney cancer. She is also a member of the Nuclear Dynamics and Cancer Research Program.
Galluzzi’s work focuses on the links between cellular pathways of response to stress and the preservation of organism stability, with a particular focus on anticancer immunity. In addition to his position at Fox Chase, he is also Associate Director of the European Academy for Tumor Immunology and a founding member of the European Research Institute for Integrated Cellular Pathology.